Visus Therapeutics™ is a clinical-stage company developing innovative medicines to improve vision for people around the world. Our lead program is BRIMOCHOL, a prescription eye drop being studied to correct the loss of near vision associated with presbyopia.
With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is BRIMOCHOL™ (carbachol + brimonidine tartrate), an eye drop being evaluated to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.
Media contact: email@example.com
June 15, 2021
March 25, 2021
March 16, 2021